14 dec: Rias FY: Indtjeningen og udbyttet løftes
14 dec: Dong Energy sikrer sig partner til havmølleprojekt i USA
14-12-2016 13:43:46

Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine

Relateret indhold
16 mar - 
Aktier/middag: Genmab rykker igen mod rekord i grønt ma..
16 mar - 
Bavarian/Jyske: Endnu et løftet kursmål efter regnskab ..
16 mar - 
Aktier/åbning: Lille plus med Nets og Genmab i toppen
Relateret debat
27 mar - 
Har kigget i krystalkuglen ....
27 mar - 
Hvorfor tror du det?
27 mar - 
Aktien stryger forbi kurs 359 i morgen ...... :)

COPENHAGEN, Denmark, December 14, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has completed enrollment of 400 subjects in a Phase 2 clinical study of MVA-BN® RSV, a novel, broad spectrum, vaccine candidate against RSV (respiratory syncytial virus).

The study is evaluating the safety and immunogenicity of different doses of MVA-BN RSV in healthy subjects aged 55 or older. Top-line results from the study are anticipated in mid-2017 and will provide essential information for subsequent, larger efficacy studies.

 

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "We are very pleased to finalize enrollment in this study. Maintaining our pace of development in this highly underserved disease area is a key priority for Bavarian Nordic. We look forward to reporting data from this study, which will not only provide additional proof of concept for our multi-targeted approach, but will also help us to better understand the dosing requirements for patients as we progress to larger studies."

About MVA-BN RSV

MVA-BN RSV represents a new vaccine approach specifically designed to target five different RSV proteins to ensure a broad immune response against both RSV subtypes (A & B). Extensive preclinical studies have shown that MVA-BN RSV induces a balanced immune response comprised of both antibodies and T cells, in a similar fashion to the natural response to an RSV infection. These results were confirmed in a Phase 1 study in healthy adults, reported in May 2016, which showed that MVA-BN RSV significantly boosted antibodies and T cells against both RSV subtypes. The vaccine was well tolerated, with no unexpected or serious adverse reactions. The vast majority of events represented local and systemic reactions typical for vaccines.

About RSV

Respiratory syncytial virus, or RSV, is the most common cause of bronchiolitis and pneumonia in infants and a significant cause of respiratory illness in older adults, resulting in a high number of hospitalizations. RSV infections are responsible each year for a similar number of deaths as the flu in children up to age 14, as well as in the elderly population. It is estimated that more than 64 million people are infected globally each year, yet unlike the flu, there is no vaccine to prevent RSV, presenting a large unmet medical need and market opportunity.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

2016-12-14-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 775160.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 mar
BAVA
Det ville være dejligt - men det tror jeg ikke, vi er vist i en periode hvor den lige skal konsulere..
10
27 mar
BAVA
Shorter har reduceret med 0,07% i dag - dvs shorterne over 0,5% ligger nu på 6,37%   https://oasm.fi..
7
22 mar
BAVA
Det var en shorter, som bankede den ned her til eftermiddag. Bogle investment. Kommer ind med et sho..
7
21 mar
BAVA
Der er jo intet nyt - når en aktier falder meget går jeg altid direkte på OMX for at se om der er ko..
7
21 mar
BAVA
Her er der lidt læsning til aften kaffen..   http://www.bavarian-nordic.com/media/239960/2016-ar-sum..
7
24 mar
BAVA
Den anden store shorter marshall har reduceret med 0,12 %. Strøjer
6
23 mar
BAVA
Millennium reducerer deres short fra 1,28 til 1,16 Reduceret fra 1,40 til 1,16 fra d. 19 til i går. ..
6
27 mar
BAVA
Det er netop i dette tilfælde hvor shorter er positivt. De holder i øjeblikket hånden under aktien, ..
4
23 mar
BAVA
Ja aktien har en kæmpe upside og en relative lille downside, et lille pust så er aktien over kurs 40..
4
25 mar
BAVA
Håber denne version er mere læsbar:Bavarian Nordic indsendte i fredags flere patentansøgninger på et..
3

Aktier/tendens: Forårstemningen har nu igen fundet vej til markedet

28-03-2017 08:28:42
Investorernes humør er noget højere tirsdag morgen, end tilfældet var mandag eftermiddag, da de danske handlere slukkede for deres skærme efter et fald i C20 Cap-indekset på 0,4 pct.Skuffelsen over Trumps nederlag i Kongressen fredag er ifølge iagttagere vendt til håb om, at Trump-administrationen snart får held til at gennemføre en hurtig reform med lettelser på skatteområdet. Den optimisme har s..

SAS overdrager to landingstilladelser i Heathrow for 75 mio. dollar

27-03-2017 16:23:30
SAS overdrager to landingstilladelse i London Heathrow, og det giver en positiv resultateffekt på 75 mio. dollar.Det oplyser SAS.De 75 mio. dollar vil blive indtægtsført i andet kvartal af SAS' regnskabsår 2016/2017.Med overdragelsen er SAS' landingstilladelser, såkaldte slots, reduceret til 17.SAS har dog aftalt, at selskabet kan benytte de to slots i op til tre år, og overdragelsen får således i..

Aktier/middag: Mærsk tager bundplacering i middagshandlen

27-03-2017 12:00:29
A.P. Møller-Mærsks aktier falder mandag middag og tager bundplaceringen i C20 Cap-indekset. Dermed følger aktien den trend, der ligeledes ses ude i Europa, hvor råvaresektoren samlet ligger til et fald på 1,5 pct. i det brede europæiske Stoxx 600-indeks.- Vi ser, at olie og råvarer sætter sig lidt i dag, og det slår igennem hos Mærsk, siger Mads Zink, der chefhandler i Danske Bank, til Ritzau Fina..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/Nykredit: Ser risiko for let dukkert på aktiemarkedet
2
Aktier/tendens: Forårstemningen har nu igen fundet vej til markedet
3
Nordea/økonom: Flytning af hovedkvarter vil halvere statsunderskud
4
Canadiske potaktier i topform efter ventet legalisering til juli
5
Mandagens aktier: Mærsk vendte snuden ned i rødt indeks

Relaterede aktiekurser

Bavarian Nordic A/S 348,00 0,1% Stigning i aktiekurs
Bavarian Nordic DKK10 49,68 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. marts 2017 12:11:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB7 - 2017-03-28 12:11:50 - 2017-03-28 12:11:50 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x